Register now for the
MATRICS Consensus Development for Functional Endpoints in Schizophrenia Research
August 21-22, Bethesda, MD
|OVERVIEW||COMMITTEES||MEETINGS & PRESENTATIONS||CONSENSUS BATTERY||RECOMMENDATIONS TO FDA||LINKS|
deficits -- including impairments in areas such as memory, attention,
and executive function -- are
a major determinant and predictor of long-term disability in schizophrenia.
Unfortunately, available antipsychotic medications
are relatively ineffective in improving cognition. Scientific discoveries
during the past decade suggest that there may be opportunities for developing
medications that will be effective for improving cognition in schizophrenia.
The MATRICS program will bring together representatives of academia, industry, and government in a consensus process for addressing all of these obstacles.
Funding for MATRICS is provided by the NIMH Division of Mental Disorders, Behavioral Research, and AIDS (Ellen Stover, Division Director; Wayne Fenton, NIMH Deputy Director for Clinical Affairs). The Contract was awarded to UCLA in September, 2002 with Stephen R. Marder, M.D. as P.I. and Michael F. Green, Ph.D. as Co-P.I.
Contact email@example.com for questions or comments about the MATRICS program and see our website - www.matricsinc.org - for details regarding the MATRICS Consensus Cognitive Battery (MCCB).
Contact firstname.lastname@example.org for questions or comments about with this web site.
|Revised: Monday, 26-Oct-2009 12:45:51 PST|